D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
The effects of structural damage on functional disability in psoriatic arthritis
TL;DR: In PsA, structural damage, particularly JSN, has implications for physical function, and this needs to be considered when targeting functional outcomes in clinical practice.
Journal ArticleDOI
Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients.
TL;DR: In early RA, progression of joint damage increases with increasing disease activity on MTX, which indicates that beyond cytokine blockade (TNF- and IL-6 inhibitors), also cell-directed therapy (anti-CD20 antibody) conveys profound anti-destructive effects and dissociates the link between disease activity and joint damage.
Journal ArticleDOI
Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
Ernest Choy,Daniel Aletaha,Frank Behrens,Axel Finckh,Juan J. Gomez-Reino,Jacques-Eric Gottenberg,Florian Schuch,Andrea Rubbert-Roth +7 more
TL;DR: The challenges surrounding bDMARD therapy and the benefit/risk ratio of biologic monotherapy when compared with combination with a csDMARD will be discussed, and insights into these important issues are provided.
Journal ArticleDOI
Treating rheumatic patients with a malignancy
Katarzyna Elandt,Daniel Aletaha +1 more
TL;DR: The decision to treat a patient with a history of cancer immunosuppressively should be shared by the rheumatologist and the oncologist once the decision is established, because such patients need intensive and close monitoring.
Journal ArticleDOI
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Daniel Aletaha,Jen-Fue Maa,Su Chen,Sung-Hwan Park,Dave Nicholls,Stefan Florentinus,Daniel Furtner,Josef S Smolen +7 more
TL;DR: Number of prior DMARDs and disease duration affect responses to therapy in patients with established RA and, regardless of disease duration, has a limiting effect on the potential response to adalimumab therapy.